

Vertex banal surged Monday aft its competitor, Sionna Therapeutics (SION), missed the people for its highly anticipated cystic fibrosis treatment. Sionna's drug, SION-719, lowered sweat chloride by 1 millimole per liter, connected mean and compared to a placebo, erstwhile added to Vertex Pharmaceuticals' (VRTX) Trikafta. Measuring chloride, oregon salt, successful sweat is the golden modular for diagnosing cystic fibrosis, a…
Copyright ©2026 Investor's Business Daily, LLC. All rights reserved. 87990cbe856818d5eddac44c7b1cdeb8
Related news
How Vertex Regained Its Footing On A Competitor's Bullish Report
8/03/2026 Vertex banal regained its footing Tuesday, rising connected a beardown second-quarter study and amid heightened expectations for its kidney disease...
8/03/2026 Vertex banal regained its footing Tuesday, rising connected a strong...

2 weeks ago
13








English (CA) ·
English (US) ·
Spanish (MX) ·